

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

Title: Patient Access to Therapeutic Medications Under Michigan Medicaid

Introduced by: David T. Walsworth, MD, for the Ingham County Delegation

Original Author: David T. Walsworth, MD

Referred to: Reference Committee A

House Action: Adopted as Amended.

Whereas, a large portion of mental health care for Michigan residents is provided by primary care physicians, and

Whereas, validated evidence-based diagnostic scales exist for many mental health conditions, including adult attention deficit disorder and adult attention deficit disorder with hyperactivity, and

Whereas, Michigan does not have an adequate supply of psychiatrists to provide access to care for all Michigan residents requiring mental health care, and

Whereas, Michigan Medicaid currently carves out payment for all mental health pharmaceuticals, and

Whereas, the pharmacy benefit manager for Michigan Medicaid declines payment for all stimulants written by physicians other than psychiatrists, regardless of diagnostic information provided, and

Whereas, some patients in areas of Michigan are being required to undergo formal neurodiagnostic and/or psychodiagnostic testing prior to being granted access to a psychiatrist's care, and

Whereas, there is little evidence to support the use of formal neurodiagnostic and/or psychodiagnostic testing in the diagnosis of adult attention deficit disorder or adult attention deficit disorder with hyperactivity, and

Whereas, unnecessary testing increases cost without adding value to the care provided, and

Whereas, care is being denied unless this unnecessary testing is performed; therefore be it

RESOLVED: That our Michigan State Medical Society work with our Michigan Department of Community Health and other interested parties to develop prior authorization policies and procedures to ensure that our adult patients with attention deficit disorder and attention deficit disorder with hyperactivity have appropriate access to evidence-based therapies, including stimulants.

WAYS AND MEANS COMMITTEE FISCAL NOTE: NONE